SCHEMBL19699266

SCHEMBL19699266

O=P(O)(O)OC[C@H]1O[C@@H](n2c(NCc3ccccc3)nc3c(/C=C/c4ccccc4)ncnc32)C[C@@H]1O

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ DNPH1 O43598 1/20 0.46
▸ TRPM2 O94759 1/20 0.45
▸ SLC28A2 O43868 2/20 0.42
▸ HSPA8 P11142 1/20 0.42
▸ NT5E P21589 1/20 0.41
▸ SIRT2 Q8IXJ6 1/20 0.40
▸ SIRT1 Q96EB6 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ P2RX3 P56373 1/20 0.40
▸ P2RX2 Q9UBL9 1/20 0.40
▸ TYMS P04818 2/20 0.40
▸ IMPDH2 P12268 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19699217 0.87 TRPM2 (0.58) DNPH1TRPM2SLC28A2HSPA8SIRT2
SCHEMBL19699207 0.86 DNPH1 (0.58) DNPH1SLC28A2HSPA8NT5ESIRT2
SCHEMBL19699229 0.81 POLB (0.56) DNPH1NT5EPOLBIMPDH2
SCHEMBL19699224 0.80 DNPH1 (0.51) DNPH1TRPM2SLC28A2HSPA8NT5E
SCHEMBL19699208 0.77 SIRT2 (0.49) DNPH1SLC28A2HSPA8NT5ESIRT2
SCHEMBL19699209 0.75 DNPH1 (0.74) DNPH1NT5EPOLBP2RX3P2RX2
SCHEMBL8979282 0.74 TRPM2 (0.61) TRPM2SIRT2SIRT1POLBTYMS
SCHEMBL17363546 0.73 SIRT2 (0.58) DNPH1TRPM2SIRT2SIRT1IMPDH2
SCHEMBL17363547 0.73 SIRT2 (0.58) DNPH1TRPM2SIRT2SIRT1IMPDH2
SCHEMBL16871847 0.73 SIRT2 (0.58) DNPH1TRPM2SIRT2SIRT1IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 — — US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 — — US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 DNPH1 2051/4885TRPM2 4847/4885SLC28A2 305/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 DNPH1 2035/4885TRPM2 4843/4885SLC28A2 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback